Correction

ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes


*Correspondence: syfuchs@upenn.edu
https://doi.org/10.1016/j.cmet.2024.04.002

(Cell Metabolism 34, 1342–1358.e1–e7; September 6, 2022)

Several mistakes were found in the originally published article. These include inadvertent use of an incorrect panel in Figures 2D and 2E, errors in data entry and resulting panels for Figures S6F and S6G, and erroneous designation for the x/y axis in Figure S2E. None of these mistakes affected overall results, study outcome, or any conclusions made. The authors sincerely regret these errors and apologize for any inconvenience or confusion caused.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.cmet.2024.04.002.
Figure 2. CH25H is a pivotal regulator of CTL trogocytosis, survival, and activity
Figure S2E. CH25H is a pivotal regulator of CTL trogocytosis, survival and activity, Related to Figure 2
Figure S6. TAK981 sumoylation inhibitor upregulates CH25H, inhibits trogocytosis and augments CAR T viability and anti-tumor activities, Related to Figure 6.